Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020.
Nomah DK, Jamarkattel S, Bruguera A, Moreno-Fornés S, Díaz Y, Alonso L, Aceitón J, Llibre JM, Domingo P, Saumoy M, Homar F, Fanjul F, Navarro J, de la Mora L, Knobel H, Orti A, Martin-Iguacel R, Miró JM, Casabona J, Reyes-Urueña J. Nomah DK, et al. Among authors: llibre jm. Open Forum Infect Dis. 2024 Mar 8;11(4):ofae132. doi: 10.1093/ofid/ofae132. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38560603 Free PMC article.
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Martínez E, et al. Among authors: llibre jm. N Engl J Med. 2003 Sep 11;349(11):1036-46. doi: 10.1056/NEJMoa021589. N Engl J Med. 2003. PMID: 12968087 Free article. Clinical Trial.
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Knobel H, Miró JM, Mahillo B, Domingo P, Rivero A, Ribera E, Gonzalez J, Sanz J, González A, Blanco JL, Boix V, Force L, Llibre JM, Dalmau D, Arroyo JA, De la Torre J, Rodriguez D, Montes ML, Arranz A, Sarasa M; Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Knobel H, et al. Among authors: llibre jm. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1276-81. doi: 10.1097/01.qai.0000137372.18814.34. J Acquir Immune Defic Syndr. 2004. PMID: 15385735 Clinical Trial.
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group. Pérez-Elias MJ, et al. Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9. Enferm Infecc Microbiol Clin. 2009. PMID: 19218000 Clinical Trial.
The changing face of HIV/AIDS in treated patients.
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. Llibre JM, et al. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633. Curr HIV Res. 2009. PMID: 19601771 Review.
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, Curran A, Santos JR, Caballero E, Bravo I, Gayá F, Domingo P, Rivero A, Falcó V, Clotet B, Ribera E. Imaz A, et al. Among authors: llibre jm. J Antimicrob Chemother. 2011 Feb;66(2):358-62. doi: 10.1093/jac/dkq432. Epub 2010 Dec 14. J Antimicrob Chemother. 2011. PMID: 21172789
267 results